Magenkarzinom pp 186-197 | Cite as

Chemotherapie des fortgeschrittenen Magenkarzinoms bei älteren Patienten und Risikopatienten

  • P. Preusser
  • H. Wilke
  • W. Achterrath
  • U. Fink
Conference paper


Das Magenkarzinom ist in der Bundesrepublik die zweithäufigste Todesursache bei den malignen Neoplasien. Pro Jahr sterben 28 von 100000 Einwohner an einem Magenkarzinom [25].


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Achterrath W, Raettig R, Franks CR, Seeber S (1984) Aktuelle Cisplatinderivate. Beitr Onkol 18:58–82Google Scholar
  2. 2.
    Aisner J, Van Echo DA, Whitacre C, Wiernik PH (1982) A phase I trial of continuous infusion VP16–213 (Etoposide). Cancer Chemother Pharmacol 7: 157–160PubMedGoogle Scholar
  3. 3.
    Beretta G, Fraschini P, Labianca R, Luporini G (1982) The value of FAM polychemotherapy in advanced gastric carcinoma. (Abstract) Proc Am Soc Clin Oncol 103: C-400Google Scholar
  4. 4.
    Beretta G, Fraschini P, Labianca R, Arnoldi E, Pancera G, Tedeschi M, Tedeschi L, Luporini G (1986) Weekly 5-fluorouracil (F) versus combination chemotherapy for advanced gastrointestinal carcinomas. A prospective study program. (Abstract) Proc Am Soc Clin Oncol 94: C-367Google Scholar
  5. 5.
    Biran H, Sulkes A (1984) A possible dose-response relationship in „FAM“ chemotherapy for advanced gastric cancer (abstract). Proc Am Soc Clin Oncol 132: C-515Google Scholar
  6. 6.
    Bonomi PB, Blessing JA, Stehmann FB, DiSaia PJ, Walton L, Major FJ (1985) Randomized trial of three cisplatin dose schedules in squamous-cell carcinoma of the cervix: A gynecologic oncology group study. J Clin Oncol 3: 1079–1085PubMedGoogle Scholar
  7. 7.
    Cartei G (1985) 5-Fluorouracil, Adriamycin und Mitomycin C beim metastasierenden Magen-karzinom. In: Nagel GA, Bach F, Bartsch HH (Hrsg) Mitomycin ’85, Aktuelle Onkologie. Zuckerschwerdt, München, S 56–64Google Scholar
  8. 8.
    Cazap EL, Gisselbrecht Ch, Smith FP, Estevez RA, Alvarez CA, Lagarde C, Hannols A et al (1986) Phase II trials of 5-FU, Doxorubicin, and Cisplatin in advanced, measurable adenocarcinoma of the lung and stomach. Cancer Treat Rep 70: 781–783PubMedGoogle Scholar
  9. 9.
    Cersosismo RJ, Hong WK (1986) Epirubicin: a review of pharmacology, clinical activity, and adverse effects of an adriamycin analogue. J Clin Oncol 4: 425–439Google Scholar
  10. 10.
    Cocconi G, DeLisi V, Di Blasio B (1982) Randomized comparison of 5-FU alone or combined with mitomycin and cytarabine (MFC) in the treatment of advanced gastric cancer. Cancer Treat Rep 66: 1263–1266PubMedGoogle Scholar
  11. 11.
    Comis RL (1979) Mitomycin C in gastric cancer. In: Mitomycin C — current status and new developments. Carter SK, Crooke ST (eds) Academic Press, New York, pp 129–137Google Scholar
  12. 12.
    De Lisi V, Cocconi G, Tonato M, Di Costanzo F, Leonardi F, Soldani M (1986) Randomized comparison of 5-FU alone or combined with carmustine, and mitomycin (BAFMi) in the treatment of advanced gastric cancer: a phase III trial of the Italian clinical research oncology group (GOIRC). Cancer Treat Rep 70: 481–485PubMedGoogle Scholar
  13. 13.
    DeSimone PA, Gams R, Birch R (1986) Phase II evaluation of mitoxantrone in advanced carcinoma of the stomach: a southwestern cancer study group trial. Cancer Treat Rep 70: 1043–1044PubMedGoogle Scholar
  14. 14.
    Doll DC, Weiss RB, Issell BF (1985) Mitomycin: ten years after approval for marketing. J Clin Oncol 3: 276–286PubMedGoogle Scholar
  15. 15.
    Dorr RT, Fritz WL (1980) Doxorubicin. Cancer chemotherapy handbook. Elsevier, New York, pp 388–401Google Scholar
  16. 16.
    Dorr, RT, Fritz WL (1980) Carmustine. Cancer chemotherapy handbook. Elsevier, New York, pp 295–302Google Scholar
  17. 17.
    Dorr RT, Fritz WL (1980) 5-Fluorouracil. Cancer chemotherapy handbook. Elsevier, New York, pp 435–449Google Scholar
  18. 18.
    Douglass HO, Trave F, Milliron S, Baroni M, Nava H, Emrich LJ, Rustum YM (1987) A phase II trial of 5-fluorouracil and highdose intravenous leukovorin in gastric carcinoma. J Clin Oncol 5: 1150–1156PubMedGoogle Scholar
  19. 19.
    Douglass HO Jr, Lavin PT, Goudsmit A, Klaasen DJ, Paul AR (1984) An eastern cooperative oncology group evaluation of combinations of methyl-CCNU, mitomycin C, adriamycin, and 5-fluorouracil in advanced measurable gastric cancer (EST 2277). J Clin Oncol 2: 1372–1381PubMedGoogle Scholar
  20. 20.
    Fausti SA, Schechter MA, Rappaport BZ, Rey RH, Mass RE (1984) Early detection of cispla-tin ototoxicity. Cancer 53: 224–231PubMedCrossRefGoogle Scholar
  21. 21.
    Figoli F, Galligioni E, Crivellari D, Vaccher E, Lo Re G, Tumolo S, Veronesi A et al (1986) Cisplatin (DDP) in combination with adriamycin (A) and fluorouracil (F) (DAF) in advanced gastric cancer — a phase II study (abstract). Proc Am Soc Clin Oncol 95: C-369Google Scholar
  22. 22.
    Fornasiero A, Cartei G, Daniele O, Fosser V, Fiorentino MV (1984) FAM2 regimen in disseminated gastric cancer. Tumori 70: 77–80PubMedGoogle Scholar
  23. 23.
    Franke H (1984) Wesen und Bedeutung der Polypathie und Multimorbidität in der Altersheilkunde. Internist 25: 451–455PubMedGoogle Scholar
  24. 24.
    Gallmeier WM (1977) Krebstherapie im Alter. MMW 43: 1379–1380Google Scholar
  25. 25.
    Statistisches Bundesamt Wiesbaden (1984) Gesundheitswesen, Fachserie 12, Todesursachen 1983. Statistisches Bundesamt, Wiesbaden, W Kohlhammer, Stuttgart, S 12–19Google Scholar
  26. 26.
    Greco FA, Johnson DH, Hande RK, Porter LL, Hainsworth JD, Wolff SN (1985) High-dose Etoposide (VP-16) in small-cell lung cancer. Sem Oncol 12 [Suppl 2]: 42–44Google Scholar
  27. 27.
    Haas C, Oishi N, McDonald B, Coltman C, O’Bryan R (1983) Southwest oncology group phase I—III gastric cancer study: 5-fluorouracil, adriamycin, and Mitomcin C ± Vincristine (FAM vs V-FAM) compared to Chlorozotocin (CZT), M-AMSA, and Dihydroxyanthracene-dione (DHAD) with unimpressive differences (abstract). Proc Am Soc Clin Oncol (2) 122: C-478Google Scholar
  28. 28.
    Haim N, Cohen Y, Honigman J, Robinson E (1982) Treatment of advanced gastric carcinoma with 5-fluorouracil, adriamycin and mitomycin C (FAM). Cancer Chemother Pharmacol 8: 277–280PubMedCrossRefGoogle Scholar
  29. 29.
    Haim N, Epelbaum R, Cohen Y, Robinson E (1984) Further studies in the treatment of advanced gastric cancer by 5-fluorouracil, adriamycin (doxorubicin), and mitomycin C (modified FAM). Cancer 54: 1999–2002PubMedCrossRefGoogle Scholar
  30. 30.
    Herrmann R, Fritze D, Queißer W, Flechtner H, Ho AD, Schlag P, König H (1984) Chemotherapie des Magenkarzinoms. Dtsch med Wochenschr 109: 1704Google Scholar
  31. 31.
    Hill BT (1986) Potential of continuous tumor cell lines for establishing patterns of cross-resistance and collateral sensitivity in vitro. Drugs Exp Clin Res 12: 293–298PubMedGoogle Scholar
  32. 32.
    Hunter CP, Frelick RW, Feldman AR, Bavier AR, Dunlap WH, Ford L, Henson D et al (1987) Selection factors in clinical trials: results from the cummunity clinical oncology program physician’s patient log. Cancer Treat Rep 71: 559–565PubMedGoogle Scholar
  33. 33.
    Kelsen DP, Magill G, Cheng E, Coonley C, Yagoda A (1982) Phase II trial of etoposide (VP16) in the treatment of upper gastrointestinal malignancies (abstract). Proc Am Soc Clin Oncol 96: C-371Google Scholar
  34. 34.
    Kim NK (1984) Chemotherapy of advanced gastric carcinoma with 5-fluorouracil, adriamycin, mitomycin (FAM), and 5-fluorouracil, adriamycin, cisplatin (FAP) combinations: experience in Korea. In: Ogawa M, Muggia FM, Rozencweig M (eds) Adriamycin, its expanding role in cancer treatment. Excerpta Medica, Amsterdam, pp 137–145Google Scholar
  35. 35.
    Klein HO, Wickramanyake PD, Farkh G-R (1986) 5-Fluorouracil (5-FU), adriamycin (ADM), and methotrexate (MTX)-a combination protocol (FAMTX) for treatment of metastasized stomach cancer (abstract). Proc Am Soc Clin Oncol 84: C-325Google Scholar
  36. 36.
    Kolaric K, Potrebica V, Stanovnik M (1986) Controlled phase III clinical study of 4-epidoxo-rubicin + 5-fluorouracil versus 5-fluorouracil aJone in metastatic gastric and rectosigmoid cancer. Oncology 43: 73–77PubMedCrossRefGoogle Scholar
  37. 37.
    Kris MG, Gralla RJ, Clark RA, Tyson LB, Wertheim MS, Kelsen DP (1985) Incidence, course, and severity of delayed nausea and vomiting following the administration of high-dose cisplatin. J Clin Oncol 3: 1379–1384PubMedGoogle Scholar
  38. 38.
    Lee YJ, Catane R, Rozencweig M, Bono VH, Muggia FM, Simon R, Staquet MS (1979) Analysis and interpretation of response rates for anticancer drugs. Cancer Treat Rep 63: 1713–1720PubMedGoogle Scholar
  39. 39.
    Legha SS, Dimery IW (1985) High-dose cisplatin administration without hypertonic saline: observation of disabling neurotoxicity. J Clin Oncol 3: 1373–1378PubMedGoogle Scholar
  40. 40.
    Leichmann L, MacDonald B, Dindogru A, Samson M (1982) Platinum: a clinical active drug in advanced adenocarcinoma of the stomach (abstract). Proc Am Assoc Cancer Res 110: 430Google Scholar
  41. 41.
    Levi JA, Dalley DN, Aroney RS (1979) Improved combination chemotherapy in advanced gastric cancer. Br Med J 2: 1471–1473PubMedCrossRefGoogle Scholar
  42. 42.
    Levi JA, Fox RM, Tattersall MH, Woods RL, Thomson D, Gill G (1986) Analysis of a prospective randomized comparison of doxorubicin versus 5-fluorouracil, doxorubicin, and BCNU in advanced gastric cancer: implications for future studies. J Clin Oncol 4: 1348–1355PubMedGoogle Scholar
  43. 43.
    Lipschitz DA (1985) Conference: cancer in the elderly: basic science and clinical aspects. Ann Intern Med 102: 218–228PubMedCrossRefGoogle Scholar
  44. 44.
    Lopez M, Di Lauro L, Papaldo P, Conti EMS (1986) Treatment of advanced measurable gastric carcinoma with 5-fluorouracil, adriamycin, and BCNU. Oncology 43: 288–291PubMedCrossRefGoogle Scholar
  45. 45.
    Lopez M, Perno CF, Di Lauro L, Papaldo P (1984) 5-Fluorouracil, adriamycin, BCNU (FAB) combination chemotherapy for advanced gastric cancer. Cancer Chemother Pharmacol 12: 194–197PubMedCrossRefGoogle Scholar
  46. 46.
    Louie AC, Issell BF (1985) Amsacrine (AMSA) — a clinical review. J Clin Oncol 3: 562–592PubMedGoogle Scholar
  47. 47.
    MacDonald JS, Gunderson LL, Cohn I Jr (1985) Cancer of the stomach. In: De Vita VT, Hellman S, Rosenberg SA (eds) Cancer, principles and practice of oncology. Lippincott, Philadelphia, pp 534–552Google Scholar
  48. 48.
    MacDonald JS, Schein PS, Wooley PV, Smythe T, Ueno W, Hoth D, Smith F et al (1980) 5-Fluorouracil, doxorubicin, and mitomycin (FAM) combination-chemotherapy for advanced gastric cancer. Ann Intern Med 93: 533–536PubMedCrossRefGoogle Scholar
  49. 49.
    Machover D, Goldschmidt E, Chollet P (1986) Treatment of advanced colorectal and gastric adenocarcinomas with 5-fluorouracil and highdose folinic acid. J Clin Oncol 4: 685–696PubMedGoogle Scholar
  50. 50.
    Melamed LB, Selim MA, Schuchman D (1985) Cisplatin ototoxicity in gynecologic cancer patients. Cancer 55: 41–43PubMedCrossRefGoogle Scholar
  51. 51.
    Moertel CG (1973) Therapy of advanced gastrointestinal cancer with the nitosoureas. Cancer Chemother Rep 4: 27–34Google Scholar
  52. 52.
    Moertel CG, Fleming T, O’Connell M, Schutt M, Rubin J (1984) A phase II trial of combined intensive course 5-Fu, adriamycin and cis-platinum in advanced gastric and pancreatic carcinoma. (Abstract) Proc Am Soc Clin Oncol 137: C-535Google Scholar
  53. 53.
    Moertel CG, Lavin PT (1979) Phase II—III chemotherapy studies in advanced gastric cancer. Cancer Treat Rep 63: 1863–1869PubMedGoogle Scholar
  54. 54.
    Moertel CG, Rubin J, O’Connell MJ, Schutt AJ, Wieand HS (1986) A phase II study of combined 5-fluorouracil, doxorubicin, and cisplatin in the treatment of advanced upper gastrointestinal adenocarcinomas. J Clin Oncol 4: 1053–1057PubMedGoogle Scholar
  55. 55.
    O’Dwyer PJ, Leyland-Jones B, Alonso MT, Marsoni S, Wittes RE (1985) Etoposide (VP-16 213). N Engl J Med 312: 692–700PubMedCrossRefGoogle Scholar
  56. 56.
    Oshima K, Yamada T, Nonaka T, Aoyama M, Hirose H, Adachi N, Kobayachi S, Udo K (1982) Treatment of advanced G.I. cancer patients with 5-Fu, adriamycin, and mitomycin C (FAM). Proc 13th Intern Cancer Congress Seattle 8–15th Sept, p 665, Abstr 3977Google Scholar
  57. 57.
    Osswald H, Kunz W (1987) Therapeutic synergism of Etoposide and Fuororouracil combined sequentially in advanced leukemia L1210. (Abstract) Cancer Res Clin Oncol 113 [suppl]: 53 D-THER 39Google Scholar
  58. 58.
    Ozols RF, Ostchega Y, Myers CE, Young RC (1985) High-dose cisplatin in hypertonic saline in refractory ovarian carcinoma. J Clin Oncol 3: 1246–1250PubMedGoogle Scholar
  59. 59.
    Pannettiere FJ, Haas Ch, McDonald B, Costanzi JJ, Talley RW, Athens J, Oishi N et al (1984) Drug combinations in the treatment of gastric adenocarcinoma: a randomized southwest oncology group study. J Clin Oncol 2: 420–424Google Scholar
  60. 60.
    Preusser P, Achterrath W, Niederle N, Seeber S (1985) Cisplatin. Arzneimitteltherapie 2: 50–65Google Scholar
  61. 61.
    Preusser P, Wilke H, Achterrath W, Neuhaus B, Balleisen L, Meyer L, van de Loo J (1986) Advanced inoperable stomach cancer: a pilot study with the combination etoposide, adriamycin, and cisplatin. Anticancer Res 6: 1195–1196PubMedGoogle Scholar
  62. 62.
    Preusser P, Wilke H, Achterrath W, Fink U, Meyer J, Schmitz-Hübner U, Bünte H (1987) Advanced gastric carcinoma: a phase II study with etoposide (E), adriamycin (A), and split course cisplatin (P) = EAP. (Abstract) Proc Am Soc Clin Oncol 6: 292Google Scholar
  63. 63.
    Queißer W, Flechtner H (1986) Chemotherapy of advanced gastric carcinoma. Onkologie 9: 319–331PubMedCrossRefGoogle Scholar
  64. 64.
    Radice PA, Bunn PA, Ihde DC (1979) Therapeutic trials with VP-16–213 and VM-26: Active agents in small cell lung cancer, non-hodgkin’s lymphomas, and other malignancies. Cancer Treat Rep 63: 1231–1239PubMedGoogle Scholar
  65. 65.
    Robinson E, Haim N, Epelbaum R, Cohen Y (1985) Phase II trials in the treatment of advanced gastric cancer I — 5-fluorouracil, adriamycin and mitomycin (FAM), II — cisplatin, adriamycin and 5-fluorouracil (DAF). (Abstract) Proc Am Soc Clin Oncol 77: C-300Google Scholar
  66. 66.
    Roelofs RI, Hrushesky W, Rogin J, Rosenberg L (1984) Peripheral sensory neuropathy and cisplatin chemotherapy. Neurology 34: 934–938PubMedCrossRefGoogle Scholar
  67. 67.
    Rougier P, Droz JP, Amiel JL, Ruffier P, Theodore C, Kac J, Chavy A (1985) Gastric carcinoma: a phase II trial of chemotherapy with association 5-fluorouracil (5 FU), adriamycin (ADR) and cisplatin (DDP) (FAP protocol) in metastasized or inoperable patients. Preliminary results. Cancer Chemother Pharmacol 14 [Suppl]: 54–59Google Scholar
  68. 68.
    Schaefer SD, Post JD, Close LG, Wright CG (1985) Ototoxicity of low- and moderate-dose cisplatin. Cancer 56: 1934–1939PubMedCrossRefGoogle Scholar
  69. 69.
    Schein PS, MacDonald JS, Hoth D, Wooley PV (1978) Mitomycin C: experience in the United States, with emphasis on gastric cancer. Cancer Chemother Pharmacol 1: 73–75PubMedCrossRefGoogle Scholar
  70. 70.
    Schmoll HJ, Niederle N, Achterrath W (1981) Etoposid (VP-16–213). Klin Wochenschr 59: 1177–1188PubMedCrossRefGoogle Scholar
  71. 71.
    Schnitzler G, Queißer W, Heim ME, König H, Katz R, Fritze D, Herrmann R et al (1986) Phase III study of 5-Fu and carmustine versus 5-Fu, carmustine, and doxorubicin in advanced gastric cancer. Cancer Treat Rep 70: 477–479PubMedGoogle Scholar
  72. 72.
    Seeber S, Osieka R, Schmidt CG, Achterrath W, Crooke ST (1982) In vivo resistance towards Anthracyclines, Etoposide, and cis-diaminedichloroplatinum (II). Cancer Res 67: 4719–4725Google Scholar
  73. 73.
    The Gastrointestinal Tumor Study Group (1979) Phase II-III chemotherapy studies in advanced gastric cancer. Cancer Treat Rep 63:1871–1876Google Scholar
  74. 74.
    The Gastrointestinal Tumor Study Group (1984) Randomized study of combination chemotherapy in unresectable gastric cancer. Cancer 53: 13–17CrossRefGoogle Scholar
  75. 75.
    Tozak LK, Von Hoff DD (1984) The cardiotoxicity of anticancer agents. In: Perry MC, Yabro JW (eds) Toxicity of chemotherapy. Grune & Stratton, Orlando, pp 199–226Google Scholar
  76. 76.
    Vermorken JB, Kapteijn TS, Hart AAM, Pinedo HM (1983) Ototoxicity of cis-diamminedi-chloroplatinum (II): influence of dose, schedule, and mode of administration. J Cancer Clin Oncol 19: 55–58Google Scholar
  77. 77.
    Vestal RE (1978) Drug use in the elderly: a review of problems and special considerations. Drugs 16: 358–382PubMedCrossRefGoogle Scholar
  78. 78.
    WHO (1979) Handbook for reporting results of cancer treatment. WHO Offset Publication No.48, World Health Organization, pp 1–45Google Scholar
  79. 79.
    Wagener DJTh, Yap SH, Wobbes T, Burghouts JTM, van Dam FE, Hillen HFP, Hoogendoorn GJ et al (1985) Phase II trial of 5-fluorouracil, adriamycin, and cisplatin (FAP) in advanced gastric cancer. Cancer Chemother Pharmacol 15: 86–87PubMedCrossRefGoogle Scholar
  80. 80.
    Wälder S, Green M, Muggia F (1985) The role of anthracyclines in the treatment of gastric cancer. Cancer Treat Rev 12: 105–132CrossRefGoogle Scholar
  81. 81.
    Waterhouse JAH (1985) Epidemiology of gastric cancer. In: Preece PE, Cuschieri A, Wellwood JM (eds) Cancer of the stomach. Grune & Stratton, London, pp 1–32Google Scholar
  82. 82.
    Weiss RB, Issell BF (1982) The nitrosoureas: carmustine (BCNU) and lomustine (CCNU). Cancer Treat Rev 9: 313–330PubMedCrossRefGoogle Scholar
  83. 83.
    Weiss RB, Sarosy G, Clagett-Carr K, Russo M, Leyland-Jones B (1986) Anthracycline analogs: the past, present, and future. Cancer Chemother Pharmacol 18: 185–197PubMedCrossRefGoogle Scholar
  84. 84.
    Wilke H, Preusser P, Achterrath W, Lenaz L, Stahl M, Schöber Chr, Mayer H-J, Link H, Schmoll H-J (1988) Leukovorin/etoposide/5-fluorouracil in patients during cardiac risks or elderly patients suffering from advanced gastric carcinoma — a phase I/II study. Submitted to Cancer Treat Rep.Google Scholar
  85. 85.
    Wils J, Bleiberg H, Dalesio O, Blijham G, Mulder N, Planting A, Splinter Z, Duez N (1987) An EORTC gastrointestinal group evaluation of the combination of sequential methotrexate and 5-Fluorouracil, combined with adriamycin in advanced measurable gastric cancer. J Clin Oncol 4: 1799–1803Google Scholar
  86. 86.
    Wiltshaw E (1983) Chemotherapy of ovarian malignancies at the Royal Marsden Hospital. In: Bender HG, Beck L (eds) Carcinoma of the ovary. Fischer, Stuttgart, pp 169–170Google Scholar
  87. 87.
    Wiltshaw E, Evans B, Rustin G, Baker J, Barker G (1986) A prospective randomized trial comparing high-dose cisplatin with low-dose cisplatin and chlorambucil in advanced ovarian carcinoma. J Clin Oncol 4: 722–729PubMedGoogle Scholar
  88. 88.
    Wooley P, Smith F, Estevez R, Gisselbrecht C, Alvarez C, Boiron M, Machado C et al (1981) A phase II trial of 5-Fu, adriamycin and cisplatin (FAP) in advanced gastric cancer. (Abstract) Proc Am Soc Clin Oncol 455: C-481Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1989

Authors and Affiliations

  • P. Preusser
  • H. Wilke
  • W. Achterrath
  • U. Fink

There are no affiliations available

Personalised recommendations